A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous cd34+ cell administration in patients with refractory angina: Design of the renew study

Thomas J. Povsic*, Candice Junge, Adel Nada, Richard A. Schatz, Robert A. Harrington, Charles J Davidson, F. David Fortuin, Dean J. Kereiakes, Farrell O. Mendelsohn, Warren Sherman, Gary L. Schaer, Christopher J. White, Duncan Stewart, Kenneth Story, Douglas W. Losordo, Timothy D. Henry

*Corresponding author for this work

Research output: Contribution to journalArticle

69 Scopus citations

Fingerprint Dive into the research topics of 'A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous cd34+ cell administration in patients with refractory angina: Design of the renew study'. Together they form a unique fingerprint.

Medicine & Life Sciences